Lipoic acid ( DrugBank: Lipoic acid )


5 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis2
5Progressive supranuclear palsy1
13Multiple sclerosis/Neuromyelitis optica7
14Chronic inflammatory demyelinating polyneuropathy1
20Adrenoleukodystrophy1

2. Amyotrophic lateral sclerosis


Clinical trials : 645Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

5. Progressive supranuclear palsy


Clinical trials : 89Drugs : 107 - (DrugBank : 40) / Drug target genes : 65 - Drug target pathways : 108 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 175Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

20. Adrenoleukodystrophy


Clinical trials : 61Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries